B
Bin Peng
Researcher at Novartis
Publications - 33
Citations - 12261
Bin Peng is an academic researcher from Novartis. The author has contributed to research in topics: Imatinib mesylate & Imatinib. The author has an hindex of 20, co-authored 31 publications receiving 11727 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Brian J. Druker,Moshe Talpaz,Debra Resta,Bin Peng,Elisabeth Buchdunger,John Ford,Nicholas B. Lydon,Hagop M. Kantarjian,Renaud Capdeville,Sayuri Ohno-Jones,Charles L. Sawyers +10 more
TL;DR: STI571 is well tolerated and has significant antileukemic activity in patients with CML in whom treatment with interferon alfa had failed and demonstrates the potential for the development of anticancer drugs based on the specific molecular abnormality present in a human cancer.
Journal ArticleDOI
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
George D. Demetri,Margaret von Mehren,Charles D. Blanke,Annick D. Van den Abbeele,Burton L. Eisenberg,Peter J. Roberts,Michael Heinrich,David A. Tuveson,Samuel Singer,Milos J. Janicek,Jonathan A. Fletcher,Stuart G. Silverman,Sandra Silberman,Renaud Capdeville,Beate Kiese,Bin Peng,Sasa Dimitrijevic,Brian J. Druker,Christopher L. Corless,Christopher D.M. Fletcher,Heikki Joensuu +20 more
TL;DR: Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor, indicating that inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinalStromal tumors, which resist conventional chemotherapy.
Journal ArticleDOI
Clinical Pharmacokinetics of Imatinib
TL;DR: Pharmacokinetic studies of Imatinib in healthy volunteers and patients with CML, GIST and other cancers show that orally administered imatinib is well absorbed, and has an absolute bioavailability of 98% irrespective of oral dosage form (solution, capsule, tablet) or dosage strength (100mg, 400mg).
Journal ArticleDOI
Pharmacokinetics and Pharmacodynamics of Imatinib in a Phase I Trial With Chronic Myeloid Leukemia Patients
Bin Peng,Michael Hayes,Debra Resta,Amy Racine-Poon,Brian J. Druker,Moshe Talpaz,Charles L. Sawyers,Marianne Rosamilia,John Ford,Peter Lloyd,Renaud Capdeville +10 more
TL;DR: Analysis of PK/PD relationships indicates that the initial hematologic response depends on the administered dose for patients with chronic myeloid leukemia.
Journal ArticleDOI
Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08
Patrick Y. Wen,W. K. Alfred Yung,Kathleen R. Lamborn,Patricia L. M. Dahia,Yanfeng Wang,Bin Peng,Lauren E. Abrey,Jeffrey J. Raizer,Timothy F. Cloughesy,Karen Fink,Mark R. Gilbert,Susan M. Chang,Larry Junck,David Schiff,Frank S. Lieberman,Howard A. Fine,Minesh P. Mehta,H. Ian Robins,Lisa M. DeAngelis,Morris D. Groves,Vinay K. Puduvalli,Victor A. Levin,Charles A. Conrad,Elizabeth A. Maher,Kenneth Aldape,Michael Hayes,Laurie Letvak,Merrill J. Egorin,Renaud Capdeville,Richard Kaplan,Anthony J. Murgo,Charles D. Stiles,Michael D. Prados +32 more
TL;DR: YP3A4 inducers, such as EIAEDs, substantially decreased plasma exposure ofImatinib and should be avoided in patients receiving imatinib for chronic myelogenous leukemia and gastrointestinal stromal tumors.